Showing results (1-10 of 496) with videos related to

Sort By:
Pageof 50
The Journal of Urology|January 10, 2004
Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trialsCatherine M Tangen, Phyllis J Goodman, John J Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
Phase III prostate cancer prevention trials: are the costs justified?Ian M Thompson, Catherine M Tangen, Eric A Klein, et al.
Journal of the National Cancer Institute|February 26, 2011
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detectionAndrew J Vickers, Cathee Till, Catherine M Tangen, et al.
The Journal of Urology|November 13, 2004
Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.
The Journal of Urology|June 16, 2009
Chemoprevention of prostate cancerIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.
Urology|May 6, 2008
Does the level of prostate cancer risk affect cancer prevention with finasteride?Ian M Thompson, Catherine M Tangen, Howard L Parnes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical TrialsCatherine M Tangen, Phyllis J Goodman, Cathee Till, et al.
Pageof 50